Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6781817 | 0.88 | CHRM1 (0.42) | ALDH1A1CHRM1 | |
| SCHEMBL10927675 | 0.85 | SIGMAR1 (0.38) | SIGMAR1ALDH1A1CHRM1HTTHSD17B10 | |
| SCHEMBL7892273 | 0.83 | — | — | |
| SCHEMBL8444907 | 0.64 | CHRM1 (0.42) | ALDH1A1CHRM1HTTLMNA | |
| SCHEMBL12312225 | 0.64 | HSD17B10 (0.39) | SIGMAR1ALDH1A1CHRM1HTTHSD17B10 | |
| SCHEMBL8441881 | 0.64 | CHRM1 (0.42) | ALDH1A1CHRM1HTTHPGDKMT2A | |
| SCHEMBL8445611 | 0.64 | CHRM1 (0.42) | ALDH1A1CHRM1 | |
| SCHEMBL11354287 | 0.62 | ALDH1A1 (0.44) | ALDH1A1LMNAHPGDKMT2A | |
| SCHEMBL10968344 | 0.61 | KMT2A (0.36) | ALDH1A1HTTHSD17B10LMNAHPGD | |
| SCHEMBL20668745 | 0.61 | ALDH1A1 (0.42) | ALDH1A1LMNAHPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0709381-A1 | Heterocyclic compounds and their preparation and use | ELI LILLY AND COMPANY (US) | 1996-05-01 | — | — | EP | claimed |
| US-6720342-B2 | AZABICYCLIC COMPOUNDS USED IN TREATING A DISEASE IN THE CENTRAL NERVOUS SYSTEM CAUSED BY MALFUNCTIONING OF THE MUSCARINIC CHOLINERGIC SYSTEM. | NOVO NORDISK A/S (DK) | 2004-04-13 | — | — | US | disclosed |
| EP-1189902-B1 | 7-OXO-2-AZABICYCLO[2.2.1]HEPTANES AS SELECTIVE MUSCARINIC RECEPTOR ANTAGONIST | LILLY CO ELI (US) | 2003-08-27 | — | — | EP | disclosed |
| US-6559171-B1 | Muscarinic receptor modulators 7-oxo-2-azabicyclo(2.2.1)heptanes of formula (I) which are useful for the treatment of various diseases and conditions, for example, Alzheimer's disease, glaucoma, psychosis, | ELI LILLY AND COMPANY | 2003-05-06 | — | — | US | disclosed |
| US-20020115697-A1 | Heterocyclic compounds and their preparation and use | JEPPESEN LONE (DK) | 2002-08-22 | — | — | US | disclosed |
| EP-0900218-B1 | HETEROCYCLIC COMPOUNDS | LILLY CO ELI (US) | 2002-07-24 | — | — | EP | disclosed |
| EP-0900204-A4 | HETEROCYCLIC COMPOUNDS | LILLY CO ELI (US) | 2001-03-21 | — | — | EP | disclosed |
| US-6187798-B1 | (+-)EXO-3-(3-(4-CHLOROPHENYL)PROPYNYLOXY-4-(1 -AZABICYCLO(2.2.1)HEPTYL-3-OXY)-1,2,5-THIADIAZOLE, FOR EXAMPLE; FOR MODULATING A MUSCARINIC RECEPTOR; TREATING ALZHEIMER'S DISEASE OR PSYCHOSIS | ELI LILLY AND COMPANY | 2001-02-13 | — | — | US | disclosed |
| US-6124312-A | ACTIVE DRUG FOR TREATING ALZHEIMER'S DISEASE | ELI LILLY AND COMPANY (US) | 2000-09-26 | — | — | US | disclosed |
| US-6117883-A | Heterocyclic compounds | ELI LILLY AND COMPANY (US) | 2000-09-12 | — | — | US | disclosed |
| US-5672709-A | INTERMEDIATES FOR DRUGS USEFUL IN TREATING CENTRAL NERVOUS SYSTEM DISORDERS | ELI LILLY AND COMPANY (US) | 1997-09-30 | — | — | US | disclosed |
| WO-1997034899-A1 | HETEROCYCLIC COMPOUNDS AND THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1997-09-25 | — | — | WO | disclosed |
| US-5665745-A | 1,2,5-THIADIAZOLE DERIVATIVES FOR TREATING DISEASES OF CENTRAL NERVOUS SYSTEM | ELI LILLY AND COMPANY (US) | 1997-09-09 | — | — | US | disclosed |
| US-5646289-A | REACTING A 3-CHLORO-1,2,5-THIADIAZOLE WITH ALKALI METAL BIS(TRIALKYL OR ARYLSILYL)AMIDE; DECHLORINATION; TREATING NERVOUS SYSTEM DISORDERS | ELI LILLY AND COMPANY (US) | 1997-07-08 | — | — | US | disclosed |
| WO-1997017962-A1 | METHOD FOR TREATING ANXIETY | ELI LILLY AND COMPANY (US) | 1997-05-22 | — | — | WO | disclosed |
| EP-0774256-A1 | Use of azacyclic or azabicyclic thiadiazole compounds for treating anxiety | ELI LILLY AND COMPANY (US) | 1997-05-21 | — | — | EP | disclosed |
| WO-1996038430-A1 | PROCESS FOR MAKING HETEROCYCLIC COMPOUNDS | ELI LILLY AND COMPANY (US) | 1996-12-05 | — | — | WO | disclosed |
| WO-1996038431-A1 | PROCESS FOR MAKING HETEROCYCLIC COMPOUNDS | ELI LILLY AND COMPANY (US) | 1996-12-05 | — | — | WO | disclosed |
| EP-0745601-A1 | Process for preparing 1,2,5-thiadiazole derivatives | ELI LILLY AND COMPANY (US) | 1996-12-04 | — | — | EP | disclosed |
| EP-0709381-A1 | Heterocyclic compounds and their preparation and use | ELI LILLY AND COMPANY (US) | 1996-05-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115697-A1 | Heterocyclic compounds and their preparation and use | CHRM5, ACHE, CHRM2 | SIGMAR1 2101/4885ALDH1A1 1468/4885CHRM1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.